MRNA Moderna Inc. Loading...

From MRNA earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
Jul 31 ◎
Jamie Mock CFO, Moderna, Inc. MRNA Q2 FY26 call
Guidance is maintained, not raised, with revenue growth expected but offset by potential COVID vaccination rate declines. Core pipeline milestones (e.g., INT readout) are highlighted as key near-term value drivers.
MRNA
HIGH
12:00
May 01 ◎
Stéphane Boncel CEO, Moderna, Inc. MRNA Q1 FY26 call
Management reiterates up to 10% revenue growth for 2026, reiterates $4.2B adjusted cash costs target, and sees multiple value drivers including EU approvals and oncology pipeline catalysts.
MRNA
HIGH
13:00
Feb 13 ◎
Stéphane Boncel CEO, Moderna, Inc. MRNA Q4 FY25 call
Management expresses optimism by guiding up to 10% revenue growth for 2026, driven by international partnerships and new product approvals, while maintaining strict cost discipline.
MRNA
HIGH

About MRNA Analyst Coverage

Buzzberg tracks MRNA (Moderna Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: Jamie Mock, Stéphane Boncel.